SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as the crypto market experiences volatility, with community members debating potential support levels and whether a deeper correction is coming. Mixed sentiment abounds, as some traders anticipate a bounce while others brace for further downside, referencing historical September weakness. Broader macroeconomic concerns, including a potential government shutdown, are also being discussed as possible contributing factors.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is experiencing volatility, prompting discussions around potential government shutdowns and the impact of overnight liquidations. Community members are debating whether this is a buying opportunity or a sign of deeper issues, with some pointing to market manipulation and others awaiting key price levels. Tom Lee's previous predictions are being questioned amidst the current price action.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is trending due to a recently announced $3 billion AI hosting deal with Fluidstack, backed by Google, which includes a significant equity stake. Despite the positive news, the stock's reaction is mixed as investors digest the details of an associated convertible note offering, sparking community debate about potential dilution. Some investors view this as a strategic move to expand AI capabilities, while others express concern about the near-term impact.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending as the stock price dips following news of a $2.5 billion FTC settlement, with some traders believing this presents a buying opportunity while others anticipate further declines. Community discussions revolve around the impact of the settlement and the potential of Amazon's autonomous vehicle initiatives like Zoox. Analysts are weighing in with upgrades, but some investors express frustration with the stock's recent performance compared to its peers.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy ($MSTR) is trending as traders weigh its correlation to Bitcoin amid recent price swings, with some highlighting its potential as a leveraged play while others point to dilution risks. Community members are actively discussing key support levels and potential short squeeze opportunities, with mixed sentiment on its performance relative to direct Bitcoin ownership. Overall, the conversation revolves around $MSTR's valuation and its future trajectory in relation to the broader crypto market.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco is trending amidst discussions about its valuation, potential impact from tariffs, and recent executive membership policy changes. The community is weighing whether its defensive strength justifies its high P/E ratio, especially compared to competitors, while monitoring upcoming earnings for insights on consumer spending and tariff navigation. Some traders anticipate a potential stock split or special dividend, while others point to insider selling as a bearish indicator.

Tidal Trust II - YieldMax MSTR Option Income Strategy ETF

YieldMax MSTR Option Income Strategy ETF

MSTY is trending as investors discuss its recent dip alongside Bitcoin's movements, with some expressing concerns about NAV erosion despite the attractive dividend yield. Community members are debating whether to reinvest dividends or seek alternative investments, while closely monitoring MSTR's performance and potential support levels. Discussions also revolve around the impact of Bitcoin's price on MSTY and MSTR, with some investors awaiting potential rate cuts and S&P 500 inclusion news.

SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm initiated two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): Joint Pharma developing THX-TS01 targeted to the treatment of TS and Brain Bright Pharma developing THX-ULD01 targeted to the high value and under-served market of MCIs. Its products include SCI-110, SCI-210, SCI-160, and CannAmide. The company was founded on August 23, 2004 and is headquartered in Tel Aviv, Israel.

SciSparc Ltd

Scisparc Ltd

SPRC is trending due to community discussion around a quantum computing initiative for AI drug discovery, with retail traders debating its potential and the possibility of a short squeeze. Bullish investors are optimistic about the company's technology and are targeting a short burn, while bears point to potential dilution and low profitability. The stock's volatile price action and high short interest are also fueling the conversation.

Lithium Americas Corp. engages in the development of the Thacker Pass project. It is focused on advancing Thacker Pass to production it is located in northern Nevada. The company was founded on January 23, 2023 and is headquartered in Vancouver, Canada.

Lithium Americas Corp (NewCo)

Lithium Americas Corp

Lithium Americas Corp ($LAC) is trending due to speculation around a potential equity stake from the U.S. government as part of loan renegotiations, sparking excitement about energy independence and green/AI initiatives. The community is buzzing about the potential for a short squeeze and comparing it to previous government-backed success stories like $MP, while also debating the company's financial health and production timeline amid fluctuating lithium prices.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending as reports surface about the company seeking investment from Apple and other partnerships, fueling optimism around its comeback bid and future role in AI. The community is discussing potential price targets and the impact of government and industry support, with many viewing this as a significant turning point for the stock. Bullish sentiment is high as investors speculate on potential deals with Apple and Nvidia, envisioning a resurgence of American tech leadership.

statis crypto Watchlist

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of aTyr Pharma, Inc. (ATYR) plummeted 82% in Monday’s pre-market after the company announced that its late-stage study of Efzofitimod in 268 patients with pulmonary sarcoidosis did not meet the primary goal of steroid dose reduction from baseline at week 48.However, clinical benefit for Efzofitimod was observed across multiple study parameters, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-topline-results-phase-3-efzo-fittm-study">said</a>. aTyr Pharma announced that it plans to engage with the U.S. Food and Drug Administration (FDA) to review the results and determine the path forward for Efzofitimod in the treatment of pulmonary sarcoidosis.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ATYR">ATYR stock</a> jumped from 'bullish' to 'extremely bullish' territory over the past 24 hours, while message volume stayed at 'extremely high' levels.&nbsp;Pulmonary sarcoidosis is an inflammatory disease characterized by the formation of clumps of inflammatory cells in one or more organs of the body. It can cause permanent loss of lung function in some patients. According to the company, about 200,000 Americans live with the condition. A total of 268 patients with pulmonary sarcoidosis were enrolled in the late-stage study.The company stated that the change from baseline in mean daily oral corticosteroid dose was reduced to an average of 2.79 mg for 5.0 mg/kg Efzofitimod, compared to 3.52 mg for the placebo in the trial. Complete steroid withdrawal was achieved for 52.6% of patients treated with 5.0 mg/kg efzofitimod vs 40.2% on placebo, it added.The study, however, showed clinical improvement in the King’s Sarcoidosis Questionnaire (KSQ)-Lung score at week 48 for 5.0 mg/kg Efzofitimod compared to placebo. The questionnaire is designed to assess the impact of sarcoidosis on various aspects of life. Further, lung function was maintained at week 48, the company said. aTyr believes these findings indicate drug activity for Efzofitimod.ATYR stock is down 70% this year and approximately 43% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/trump-fed-rate-cut-this-week-too-late-powell-bigger-than-he-had-in-mind/chwwONNRdUh">Trump Says ‘Too Late’ Powell Must Cut Rates Now, And ‘Bigger Than He Had In Mind’ Ahead Of Fed Meeting This Week</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is aTyr Stock Falling Today?

The company announced that it plans to engage with the U.S. Food and Drug Administration (FDA) to review the results and determine the path forward for Efzofitimod in the treatment of pulmonary sarcoidosis.

Equity

Atyr Pharma shares fell 1.5% in volatile premarket trade on Monday, with investors on edge ahead of topline results from its pivotal Phase 3 EFZO-FIT trial of efzofitimod. The data is expected any day and will be presented at the European Respiratory Society conference.The 52-week global study, which completed its last patient visits in July, enrolled 268 pulmonary sarcoidosis patients across 85 centers in nine countries. Patients were randomized to monthly intravenous doses of efzofitimod at 3 mg/kg, 5 mg/kg, or placebo.&nbsp;The primary endpoint is steroid reduction from baseline to week 48, with secondary endpoints including symptom relief and lung function. The trial design incorporated a forced steroid taper, a key measure for assessing clinical benefit.Analysts have flagged the readout as a potential inflection point. Jefferies lifted its price target to $17 from $9 last month, citing encouraging earlier-stage data and estimating a 60% probability of statistical success. H.C. Wainwright reiterated a ‘Buy’ rating with a $35 target, Cantor Fitzgerald reaffirmed ‘Overweight’ citing strong statistical power to show steroid reduction, and Leerink Partners maintained an ‘Outperform’ rating with a $16 target.CEO Sanjay Shukla said completing EFZO-FIT, the largest interventional study ever conducted in sarcoidosis, was a milestone for patients who currently rely heavily on corticosteroids despite serious side effects.&nbsp;The company is also studying efzofitimod in systemic sclerosis-related interstitial lung disease in its ongoing Phase 2 EFZO-CONNECT trial.Atyr reported second-quarter results in August with cash, equivalents and investments of $83.2 million as of June 30. Subsequent to the quarter, it raised about $30.7 million through an at-the-market offering.&nbsp;The company said the balance is sufficient to fund operations for a year beyond the EFZO-FIT readout. R&amp;D expenses were $15.4 million in the quarter, driven by trial and manufacturing costs, while G&amp;A expenses totaled $4.9 million.On Stocktwits, retail sentiment was ‘bullish’ amid ‘extremely high’ message volume.One user described the range of possible outcomes as a “bear case” of $2 if the data disappoints, a “base case” of $10–$15 on decent results, and a “bull case” of $25–$35 if topline data are strong enough to spark a squeeze.<stembedurl>https://stocktwits.com/Phantom_Dancer/message/628638414</stembedurl>Another user said they had bought $2 call contracts to limit downside risk, noting that the position would cover losses if the stock fell toward $1.50 while leaving room to benefit if a short squeeze drove the shares higher.<stembedurl>https://stocktwits.com/navyvet1234/message/628639974</stembedurl><a href="https://stocktwits.com/symbol/ATYR">Atyr Pharma’s stock</a> has risen 66.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Atyr Pharma’s stock (ATYR) has risen 66.6% so far in 2025. (Photo credit: Getty Images)

Why Is Atyr Pharma Stock Slipping Premarket?

Investors braced for imminent Phase 3 EFZO-FIT trial results of efzofitimod, with analysts calling it a key inflection point.

5 Biotech Stocks with Highly Anticipated Pending Results

Others

Biotech M&A is heating up, making small-cap firms with breakthrough assets top acquisition targets and potential big winners for investors.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

Will Costco Wholesale ($COST) beat its quarterly EPS estimate? 
 
*Powered by Polymarket

Stocktwits

) beat its quarterly EPS estimate? 
 
*Powered by Polymarket

ATYR
aTyr Pharma, Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ATYR News

ATYR aTyr Pharma, Inc